Thanks taureanbull.
Penicillin doesn't qualify because it wasn’t developed by an ASX-listed biotech.
However, you’re correct about Relenza, initially developed by ASX-listed Biota Holdings. It was licensed to GSK in 1990 while still a pre-clinical drug (for 7% royalties). Human clinical trials commenced in 1993 and Relenza was FDA approved in 1999.
Biota later sued GSK (unsuccessfully) for failing to adequately market the drug.
Thanks taureanbull. Penicillin doesn't qualify because it wasn’t...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.70 |
Change
0.520(2.71%) |
Mkt cap ! $2.515B | |||
| Open | High | Low | Value | Volume |
| $19.39 | $19.84 | $19.28 | $5.675M | 288.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1531 | $19.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.81 | 557 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.70 |
Change
0.520 ( 2.59 %) |
||||
| Open | High | Low | Volume | ||
| $19.50 | $19.84 | $19.28 | 87628 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| NEU (ASX) Chart |